AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
A $100,000 investment can stretch a long way, particularly for a bioscience startup like New Hope Pharmaceuticals.
Just ask David Hankins, founder of the Columbia-based company. Hankins was able to happily relinquish his CEO hat thanks to a $100,000 matching investment from MdBio, a nonprofit that supports bioscience in Maryland. Now Hankins focuses on research, and the CEO he hired, Dennis Grimaud, can worry about research partnerships and opening the R&D facility in Gaithersburg.
But none of that would be happening if Hankins had put off applying for the funds: MdBio has stopped making these equity investments, citing a need to reevaluate its financial situation.
MdBio has emerged over the past 10 years as a valuable resource for Maryland's biotech community. And while the non-profit's investments are small by VC standards, the evaluation process is quick and often timely. Last year, MdBio awarded nearly $1 million.
…